Feasibility, results and endoscopic requirements of the Elipse® swallowable intragastric balloon: initial experience

被引:3
作者
Espinet Coll, Eduardo [1 ]
Carrasco Clavijos, Sonia [1 ]
Diaz Galan, Patricia [1 ]
Vila Lolo, Carmen [1 ]
Gomez Valero, Jose Antonio [1 ]
Bacchiddu, Silvia [1 ]
Irigoyen, Daniel [1 ]
Duran Pastor, Teresa [1 ]
Mora Cubells, Laura [1 ]
Juan-Creix Comamala, Antonio [1 ]
机构
[1] Hosp Univ Dexeus, Bariatr Endoscopy Unit, Barcelona, Spain
关键词
Intragastric balloon; Swallowable balloon; Elipse (R); Obesity; SMALL-BOWEL OBSTRUCTION; PROCEDURELESS GASTRIC BALLOON; WEIGHT-LOSS; OBESITY; SAFETY; MANAGEMENT; EFFICACY;
D O I
10.17235/reed.2019.6340/2019
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: the Elipse (R) intragastric balloon (EIGB) is a swallowable capsule that is filled under X-ray control. After 16 weeks, its self-releasing valve is degraded and the balloon is deflated and excreted naturally, without endoscopy. The aim of this study was to assess the feasibility of EIGB and its efficacy, duration, safety and endoscopic requirements. Methods: this is a prospective, descriptive, non-randomized study of the first patients enrolled for EIGB. An X-ray was systematically performed after placement to ensure the correct filling of the balloon.The balloon duration was determined according to its excreted visualization or by X-ray/ultrasound.The efficacy, tolerance, adverse events and their resolution outcome (endoscopic requirements), as well as the final satisfaction degree at 16 weeks, were analyzed. Results: the study included 30 patients with a basal mean weight and body mass index (BMI) of 83.3 +/- 10.7 kg and 30.6 +/- 2.7 kg/m(2). All subjects swallowed the capsule with correct X-ray control.The mean weight loss was 11.2 +/- 5.5 kg (12.1 +/- 5.8% of total weight loss ETWL], 64.7 +/- 25% of excess weight loss [EWL]), with a weight loss > 10% in 80% of patients (p < 0.05) after four months. Early elimination of the balloon with an insufficient duration (< 12 weeks) was observed in 2/24 patients (8.3%).There was an acceptable tolerance in 80%. With regard to adverse effects, one balloon was vomited up, there was one intolerance and the balloon was removed by gastroscopy and one small bowel ileal obstruction, which was removed by ileoscopy.The final satisfaction degree was good in 60% of cases. Conclusions: EIGB placement by X-ray seems feasible and safe. Although some devices have a shorter duration than expected, such as < 16 weeks in 29% patients and < 12 weeks in 8.3% of patients, an acceptable weight loss at four months was obtained.There were some adverse effects that required endoscopy, thus we advise that the procedure be supervised by a bariatric endoscopist.
引用
收藏
页码:921 / 926
页数:6
相关论文
共 27 条
  • [1] Al-Subaie S, 2017, INT J SURG CASE REP, V41, P287, DOI 10.1016/j.ijscr.2017.10.050
  • [2] A prospective pilot study of the efficacy and safety of Elipse intragastric balloon: A single-center, single-surgeon experience
    Al-Subaie, Saud
    Khalifa, Salman
    Buhaimed, Waleed
    Al-Rashidi, Shahad
    [J]. INTERNATIONAL JOURNAL OF SURGERY, 2017, 48 : 16 - 22
  • [3] The safety and efficacy of the procedureless intragastric balloon
    Alsabah, Salman
    Al Haddad, Eliana
    Ekrouf, Shehab
    Almulla, Ahmad
    Al-Subaie, Saud
    Al Kendari, Mubarak
    [J]. SURGERY FOR OBESITY AND RELATED DISEASES, 2018, 14 (03) : 311 - 317
  • [4] Complete Small-Bowel Obstruction from a Migrated Intra-Gastric Balloon: Emergency Laparoscopy for Retrieval via Enterotomy and Intra-Corporeal Repair
    Di Saverio, Salomone
    Massoni, Claudio Bianchini
    Boschi, Sergio
    Biscardi, Andrea
    Tugnoli, Gregorio
    Masetti, Michele
    Jovine, Elio
    [J]. OBESITY SURGERY, 2014, 24 (10) : 1830 - 1832
  • [5] Evidence-based Review of the Bioenterics Intragastric Balloon for Weight Loss
    Dumonceau, Jean-Marc
    [J]. OBESITY SURGERY, 2008, 18 (12) : 1611 - 1617
  • [6] Espinet Coll E, 2017, REV ESP ENFERM DIG, V109, P350, DOI [10.17235/reed.2017.4499/2016, DOI 10.17235/REED.2017.4499/2016]
  • [7] A new swallowable intragastric balloon (Elipse®). Coffee for everybody? The position of GETTEMO
    Espinet Coll, Eduardo
    Nebreda Duran, Javier
    Lopez-Nava Breviere, Gontrand
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2018, 110 (01) : 65 - 65
  • [8] Spanish Consensus Document on Bariatric Endoscopy. Part 2. Specific endoscopic treatments
    Espinet-Coll, Eduardo
    Lopez-Nava-Breviere, Gontrand
    Nebreda-Duran, Javier
    Marra-Lopez-Valenciano, Carlos
    Turro-Arau, Roman
    Miguel Esteban-Lopez-Jamar, Jose
    Munoz-Navas, Miguel
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2019, 111 (02) : 140 - 154
  • [9] Spanish Consensus Document on Bariatric Endoscopy. Part 1. General considerations
    Espinet-Coll, Eduardo
    Lopez-Nava-Breviere, Gontrand
    Nebreda-Duran, Javier
    Marra-Lopez-Valenciano, Carlos
    Turro-Arau, Roman
    Miguel Esteban-Lopez-Jamar, Jose
    Munoz-Navas, Miguel
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2018, 110 (06) : 386 - 398
  • [10] FRIMBERGER E, 1982, HEPATO-GASTROENTEROL, V29, P38